Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Inozyme Pharma Inc (INZY)

Inozyme Pharma Inc (INZY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 271,179
  • Shares Outstanding, K 61,772
  • Annual Sales, $ 0 K
  • Annual Income, $ -71,170 K
  • 60-Month Beta 1.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.01
Trade INZY with:

Options Overview Details

View History
  • Implied Volatility 168.76% ( -17.06%)
  • Historical Volatility 75.97%
  • IV Percentile 92%
  • IV Rank 73.01%
  • IV High 227.85% on 01/23/24
  • IV Low 8.93% on 10/27/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 361
  • Put/Call OI Ratio 1.15
  • Today's Open Interest 2,896
  • Open Int (30-Day) 3,832

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.35
  • Number of Estimates 5
  • High Estimate -0.30
  • Low Estimate -0.38
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.38 +0.46%
on 04/19/24
7.80 -43.55%
on 04/01/24
-1.40 (-24.14%)
since 03/22/24
3-Month
4.38 +0.46%
on 04/19/24
7.80 -43.55%
on 04/01/24
-0.17 (-3.72%)
since 01/23/24
52-Week
2.69 +63.63%
on 10/27/23
7.80 -43.55%
on 04/01/24
-1.76 (-28.57%)
since 04/21/23

Most Recent Stories

More News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inozyme Pharma, Inc. - INZY

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inozyme Pharma, Inc. ("Inozyme" or the "Company") (NASDAQ: INZY). Such...

INZY : 4.40 (+0.23%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inozyme Pharma, Inc. - INZY

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inozyme Pharma, Inc. ("Inozyme" or the "Company") (NASDAQ: INZY). Such...

INZY : 4.40 (+0.23%)
Why Earnings Season Could Be Great for Inozyme (INZY)

Inozyme (INZY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

INZY : 4.40 (+0.23%)
DaVita (DVA) to Report Q4 Earnings: What's in the Offing?

High labor costs, along with inflationary pressures, are likely to have weighed on DaVita's (DVA) fourth-quarter top line.

DVA : 133.91 (+1.05%)
EXAS : 63.53 (+1.79%)
PEN : 205.70 (+1.33%)
INZY : 4.40 (+0.23%)
Jon Soderstrom Joins Wilson Sonsini as Chief Licensing Advisor

Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, announced today that Jon Soderstrom is joining the firm as its chief...

ACHN : 0.7912 (-21.66%)
ARVN : 34.00 (-2.58%)
NXTC : 1.5300 (-4.97%)
BHVN : 39.61 (+3.34%)
INZY : 4.40 (+0.23%)
Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures

BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel...

INZY : 4.40 (+0.23%)
Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)

- Rapid and significant increase in plasma pyrophosphate (PPi) levels observed in all three subjects in lowest dose cohort (0.2 mg/kg) – - INZ-701 was...

INZY : 4.40 (+0.23%)
How Much Upside is Left in Inozyme Pharma, Inc. (INZY)? Wall Street Analysts Think 309%

The consensus price target hints at a 308.5% upside potential for Inozyme Pharma, Inc. (INZY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

INZY : 4.40 (+0.23%)
Inozyme Pharma Announces Partnership with Rady Children’s Institute for Genomic Medicine to Advance Newborn Screening for Genetic Diseases

New technology aims to expand testing to approximately 1,000 diseases and sequencing to 3.7 million newborns annually...

INZY : 4.40 (+0.23%)
Inozyme Pharma Appoints Kurt Gunter, M.D., as Chief Medical Officer

BOSTON, June 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel...

INZY : 4.40 (+0.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Inozyme Pharma Inc. is a biopharmaceutical company. It engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue and skeleton diseases. The company's product candidate consist INZ-701, which is in clinical stage. Inozyme Pharma Inc. is based in Boston,...

See More

Key Turning Points

3rd Resistance Point 4.77
2nd Resistance Point 4.69
1st Resistance Point 4.55
Last Price 4.40
1st Support Level 4.33
2nd Support Level 4.25
3rd Support Level 4.11

See More

52-Week High 7.80
Fibonacci 61.8% 5.84
Fibonacci 50% 5.24
Fibonacci 38.2% 4.64
Last Price 4.40
52-Week Low 2.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar